Literature DB >> 4042663

Adjusting for baseline measurements in the two-period crossover study: a cautionary note.

J L Fleiss, S Wallenstein, R Rosenfeld.   

Abstract

It is intuitively appealing in planning a two-period crossover study to have each patient measured on the response variable at the beginning as well as at the end of both periods, and to take the change from the value at the start of the period to the value at the end as the measure of the patient's response to the treatment given during that period. This apparently innocuous procedure may, contrary to one's intuition, produce bias in the analysis of the data for a difference between the residual effects and a difference between the direct treatment effects.

Entities:  

Mesh:

Year:  1985        PMID: 4042663     DOI: 10.1016/0197-2456(85)90002-9

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  5 in total

1.  Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects.

Authors:  C de Mey; J Matthews; R Butzer; V Schroeter; G G Belz
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

2.  The Effect of Octanoic Acid on Essential Voice Tremor: A Double-Blind, Placebo-Controlled Study.

Authors:  Soren Y Lowell; Richard T Kelley; Marika Monahan; Carly Jo Hosbach-Cannon; Raymond H Colton; Dragos Mihaila
Journal:  Laryngoscope       Date:  2018-12-25       Impact factor: 3.325

3.  Acute effects of cicletanine in angina pectoris.

Authors:  D L Murdoch; E Henderson; H J Dargie; G T McInnes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  CONSORT 2010 statement: extension to randomised crossover trials.

Authors:  Kerry Dwan; Tianjing Li; Douglas G Altman; Diana Elbourne
Journal:  BMJ       Date:  2019-07-31

5.  Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial.

Authors:  Adam Ali Ghotbi; Mikael Sander; Lars Køber; Berit Th Philbert; Finn Gustafsson; Christoffer Hagemann; Andreas Kjær; Peter K Jacobsen
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.